BMJ  2006;332:683 (25 March), doi:10.1136/bmj.332.7543.683

News

Severe adverse reactions prompt call for trial design changes

London

The first 150 words of the full text of this article appear below.

Drugs from new chemical or biological classes being tested in phase I trials—the earliest trials of a new drug in humans—should be tested in only one person at a time, a specialist said after a UK phase I trial resulted in six healthy volunteers becoming severely ill.

The young men were taking part in the first study in humans of TGN1412, a fully humanised monoclonal antibody designed to bind to CD28, a cell surface molecule on T cells which play a role in a variety of cell mediated immune reactions. The drug was being developed for the treatment of autoimmune and inflammatory diseases and leukaemia by a German company, TeGenero.

The six volunteers developed severe reactions within three hours of being given TGN1412 intravenously, while two other men who were given a placebo showed no sign of illness. One of those who was given the placebo told the BBC that . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Fortun, P., West, J., Chalkley, L., Shonde, A., Hawkey, C. (2008). Recall of informed consent information by healthy volunteers in clinical trials. QJM 101: 625-629 [Abstract] [Full text]  
• de Jager, W., Hoppenreijs, E. P A H, Wulffraat, N. M, Wedderburn, L. R, Kuis, W., Prakken, B. J (2007). Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 66: 589-598 [Abstract] [Full text]  
• Mitsuhashi, M. (2007). Ex Vivo Simulation of Drug Action: Quantification of Drug-Induced mRNA as a Bridge Between Preclinical and Clinical Trials. Clin. Chem. 53: 148-149 [Full text]  
• Hallenbeck, J., del Zoppo, G., Jacobs, T., Hakim, A., Goldman, S., Utz, U., Hasan, A., for the Immunomodulation Workshop Participants, (2006). Immunomodulation Strategies for Preventing Vascular Disease of the Brain and Heart: Workshop Summary. Stroke 37: 3035-3042 [Abstract] [Full text]  
• Day, M. (2006). Agency criticises drug trial.. BMJ 332: 1290-1290 [Full text]  
• (2006). Hit parade. BMJ 332: 1100-1100 [Full text]  
• (2006). In brief. BMJ 332: 928-928 [Full text]  
• Mayor, S. (2006). Inquiry into adverse events in trial blames drug, not study design.. BMJ 332: 870-870 [Full text]  

Rapid Responses:

Read all Rapid Responses

Negligence or incompetence? And whose?

Arun S Nanivadekar
bmj.com, 24 Mar 2006 [Full text]

Re: Learn lession to improve safety

Naidu MUR
bmj.com, 26 Mar 2006 [Full text]

The Perils of T regulatory cell manipulation

salman siddiqui
bmj.com, 27 Mar 2006 [Full text]

Allocating Blame

Michael Goodyear
bmj.com, 27 Mar 2006 [Full text]

Clinical Research in India

Michael Goodyear
bmj.com, 27 Mar 2006 [Full text]